Clinical Trials Logo

Clinical Trial Summary

The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of IBI325 in patients with advanced solid tumors


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05119998
Study type Interventional
Source Innovent Biologics (Suzhou) Co. Ltd.
Contact Yu Jinming
Phone 0531-67626073
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date February 14, 2022
Completion date October 14, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Active, not recruiting NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Recruiting NCT05119907 - Sacituzumab Govitecan in Patients With Solid Tumor Phase 2
Active, not recruiting NCT05046808 - Pharmacokinetics Study of Famitinib Malate Capsules in Healthy Subjects Phase 1
Recruiting NCT04553692 - Phase I Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed and/or Refractory Solid Cancers Phase 1
Recruiting NCT04096638 - Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors Phase 1
Completed NCT04180384 - A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients Phase 2
Recruiting NCT04673396 - Phase I Clinical Study for Evaluation of Pharmacokinetic, Safety, Tolerance of Norcantharidin Lipid Microsphere for Injection in Patients With Solid Tumor Phase 1
Recruiting NCT04475523 - Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies Phase 1
Not yet recruiting NCT04977167 - Clinical Trial of HG146 Administered to Subjects With Advanced Solid Tumors or Lymphoma Phase 1
Not yet recruiting NCT05046847 - A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors Phase 1